| Literature DB >> 34831469 |
Maria Sidorova1,2, Golo Kronenberg3,4, Susann Matthes2, Markus Petermann2,5, Rainer Hellweg4, Oksana Tuchina1, Michael Bader2, Natalia Alenina2,6, Friederike Klempin1,2,4.
Abstract
Serotonin (5-hydroxytryptamine, 5-HT) is a crucial signal in the neurogenic niche of the hippocampus, where it is involved in antidepressant action. Here, we utilized a new transgenic rat model (TetO-shTPH2), where brain 5-HT levels can be acutely altered based on doxycycline (Dox)-inducible shRNA-expression. On/off stimulations of 5-HT concentrations might uniquely mirror the clinical course of major depression (e.g., relapse after discontinuation of antidepressants) in humans. Specifically, we measured 5-HT levels, and 5-HT metabolite 5-HIAA, in various brain areas following acute tryptophan hydroxylase 2 (Tph2) knockdown, and replenishment, and examined behavior and proliferation and survival of newly generated cells in the dentate gyrus. We found that decreased 5-HT levels in the prefrontal cortex and raphe nuclei, but not in the hippocampus of TetO-shTPH2 rats, lead to an enduring anxious phenotype. Surprisingly, the reduction in 5-HT synthesis is associated with increased numbers of BrdU-labeled cells in the dentate gyrus. At 3 weeks of Tph2 replenishment, 5-HT levels return to baseline and survival of newly generated cells is unaffected. We speculate that the acutely induced decrease in 5-HT concentrations and increased neurogenesis might represent a compensatory mechanism.Entities:
Keywords: BrdU; Tph2; behavior; depression; neurogenesis; serotonin; stem cells
Mesh:
Substances:
Year: 2021 PMID: 34831469 PMCID: PMC8618971 DOI: 10.3390/cells10113240
Source DB: PubMed Journal: Cells ISSN: 2073-4409 Impact factor: 6.600
Figure 1Effects of conditional brain serotonin knockdown, followed by recovery. (A) Experimental design part I: Tph2 knockdown and Tph2 replenishment to manipulate serotonin (5-HT) levels. TetO-shTPH2 transgenic rats received daily treatment of either saline, Dox20, or Dox25 for 14 days to determine 5-HT concentrations and its metabolite, 5-HIAA, in brain tissue on day 15 following Tph2 knockdown. Another group of TetO-shTPH2 rats receiving either saline or Dox25 was held for an additional 3 weeks (no treatment, Tph2 replenishment) to analyze 5-HT and 5-HIAA levels at day 37. (B) Fourteen days of continued i.p. Dox administration into TetO-shTPH2 rats significantly decreased 5-HT levels in RN (upon Dox25) and PFC (upon Dox20 and Dox25) with no changes observed in the HC. Dunnett’s post hoc tests ** p < 0.01, *** p < 0.001. (C) Following 3 weeks without treatment (Tph2 replenishment), 5-HT levels had recovered in the RN and PFC; no differences between treatment groups were observed. (D) A significant decrease in the rate of 5-HT usage in RN, PFC, and HC was determined following Tph2 knockdown while the differences were obsolete following Tph2 replenishment; Student’s t test * p < 0.05, ** p < 0.01; RN, raphe nuclei, PFC, prefrontal cortex, HC, hippocampus. (E) Experimental design part II: Cell proliferation and survival in the dentate gyrus. At 14 days following treatment with saline, Dox20, or Dox25, a first group of TetO-shTPH2 rats received three injections of BrdU and were killed the following day to analyze cell proliferation. A second group (saline- and Dox25-treated) received two other halogenated thymidine markers for long-term analysis: CldU was injected three times on day 14 and cell survival was analyzed at day 37; IdU was injected on day 36 and rats were killed the next day. (F) Fourteen days of continued i.p. administration of Dox significantly increased the number of BrdU-positive cells in the dentate gyrus of Dox20 and Dox25 groups compared with saline. Student’s t tests * p < 0.05, *** p < 0.001. (G) No difference in cell survival (CldU) was observed compared between treatment groups; while Tph2 replenishment affects long-term cell proliferation: the number of IdU-positive cells was significantly decreased, Student’s t tests ** p < 0.01 to IdU saline control. (H) A positive correlation of CldU/IdU labeling was observed for the Dox25 group but was absent in saline control. (I) Peroxidase staining to characterize BrdU-, IdU- and CldU-labeled cells in hippocampus. BrdU and IdU injections 1 day prior to tissue collection shows the characteristic clustered distribution of proliferating cells within the SGZ that is in opposite between treatment groups, BrdU vs. IdU; CldU injected 3 weeks prior to tissue collection permits assessment of survival and reveals migration of labeled cells into the GCL. Scale bar 100 µm. BrdU, bromodeoxyuridine, CldU, 5-chloro-2′deoxyuridine, GCL, granule cell layer, IdU, 5-iodo-2′deoxyuridine, SGZ, subgranular zone. (J) Experimental design part III: Behavior response to Tph2 knockdown vs. Tph2 replenishment. Animals of the long-term group were subjected to an Open Field arena on days 15 and 35. (K) Dox25-treated TetO-shTPH2 rats spent significantly less time in the center of the arena (in percentage) that is accompanied by increased start latency to enter (in time) at both time points, days 15 and 35, compared with saline control, Tukey’s post hoc test * p < 0.05; center vs. periphery is 50%. (L) Locomotor behavior was intact; no differences were observed in activity levels (in percentage), and mean velocity (cm/s).
Number and phenotypes of BrdU- and IdU-positive cells in the SGZ/GCL. BrdU- and IdU-positive cells co-expressing Sox2 (precursor cells, type-2) or DCX (transient immature neurons, type 2b/3). All data are shown as mean ± sem. GCL, granule cell layer, SGZ, subgranular zone, (#) numbers, (%) percentage.
|
|
|
|
|
| Control (#) | 823 (43) | 227 (20) | 312 (8) |
| Dox25 (#) | 1303 (89) *** | 331 (39) * | 457 (56) * |
| Control (%) | 27.8 (2.4) | 38.4 (2.2) | |
| Dox25 (%) | 25.3 (1.8) | 34.6 (2.5) | |
|
|
|
|
|
| Control (#) | 1393 (99) | 331 (45) | 681 (67) |
| Dox25 (#) | 981 (87) ** | 296 (25) | 577 (77) |
| Control (%) | 24.6 (1.8) | 47.1 (2.9) | |
| Dox25 (%) | 30.3 (1.6) * | 58.0 (2.2) * |
*** p 0.001, ** p 0.01, * p 0.05 to control.